| Literature DB >> 23079522 |
Mariangela Urbano1, Miguel Guerrero, Jian Zhao, Subash Velaparthi, S Adrian Saldanha, Peter Chase, Zhiwei Wang, Olivier Civelli, Peter Hodder, Marie-Therese Schaeffer, Steven Brown, Hugh Rosen, Edward Roberts.
Abstract
Novel small molecule antagonists of NPBWR1 (GPR7) are herein reported. A high-throughput screening (HTS) of the Molecular Libraries-Small Molecule Repository library identified 5-chloro-4-(4-methoxyphenoxy)-2-(p-tolyl)pyridazin-3(2H)-one as a NPBWR1 hit antagonist with micromolar activity. Design, synthesis and structure-activity relationships study of the HTS-derived hit led to the identification of 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)pyridazin-3(2H)-one lead molecule with submicromolar antagonist activity at the target receptor and high selectivity against a panel of therapeutically relevant off-target proteins. This lead molecule may provide a pharmacological tool to clarify the molecular basis of the in vivo physiological function and therapeutic utility of NPBWR1 in diverse disease areas including inflammatory pain and eating disorders.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23079522 PMCID: PMC3601546 DOI: 10.1016/j.bmcl.2012.09.074
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823